Cargando…

Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis

The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in ent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurke, Robert, Bendes, Annika, Bowes, John, Koehm, Michaela, Twyman, Richard M., Barton, Anne, Elewaut, Dirk, Goodyear, Carl, Hahnefeld, Lisa, Hillenbrand, Rainer, Hunter, Ewan, Ibberson, Mark, Ioannidis, Vassilios, Kugler, Sabine, Lories, Rik J., Resch, Eduard, Rüping, Stefan, Scholich, Klaus, Schwenk, Jochen M., Waddington, James C., Whitfield, Phil, Geisslinger, Gerd, FitzGerald, Oliver, Behrens, Frank, Pennington, Stephen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598654/
https://www.ncbi.nlm.nih.gov/pubmed/36289648
http://dx.doi.org/10.3390/biomedicines10102387
_version_ 1784816395705384960
author Gurke, Robert
Bendes, Annika
Bowes, John
Koehm, Michaela
Twyman, Richard M.
Barton, Anne
Elewaut, Dirk
Goodyear, Carl
Hahnefeld, Lisa
Hillenbrand, Rainer
Hunter, Ewan
Ibberson, Mark
Ioannidis, Vassilios
Kugler, Sabine
Lories, Rik J.
Resch, Eduard
Rüping, Stefan
Scholich, Klaus
Schwenk, Jochen M.
Waddington, James C.
Whitfield, Phil
Geisslinger, Gerd
FitzGerald, Oliver
Behrens, Frank
Pennington, Stephen R.
author_facet Gurke, Robert
Bendes, Annika
Bowes, John
Koehm, Michaela
Twyman, Richard M.
Barton, Anne
Elewaut, Dirk
Goodyear, Carl
Hahnefeld, Lisa
Hillenbrand, Rainer
Hunter, Ewan
Ibberson, Mark
Ioannidis, Vassilios
Kugler, Sabine
Lories, Rik J.
Resch, Eduard
Rüping, Stefan
Scholich, Klaus
Schwenk, Jochen M.
Waddington, James C.
Whitfield, Phil
Geisslinger, Gerd
FitzGerald, Oliver
Behrens, Frank
Pennington, Stephen R.
author_sort Gurke, Robert
collection PubMed
description The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.
format Online
Article
Text
id pubmed-9598654
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95986542022-10-27 Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis Gurke, Robert Bendes, Annika Bowes, John Koehm, Michaela Twyman, Richard M. Barton, Anne Elewaut, Dirk Goodyear, Carl Hahnefeld, Lisa Hillenbrand, Rainer Hunter, Ewan Ibberson, Mark Ioannidis, Vassilios Kugler, Sabine Lories, Rik J. Resch, Eduard Rüping, Stefan Scholich, Klaus Schwenk, Jochen M. Waddington, James C. Whitfield, Phil Geisslinger, Gerd FitzGerald, Oliver Behrens, Frank Pennington, Stephen R. Biomedicines Review The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients. MDPI 2022-09-24 /pmc/articles/PMC9598654/ /pubmed/36289648 http://dx.doi.org/10.3390/biomedicines10102387 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gurke, Robert
Bendes, Annika
Bowes, John
Koehm, Michaela
Twyman, Richard M.
Barton, Anne
Elewaut, Dirk
Goodyear, Carl
Hahnefeld, Lisa
Hillenbrand, Rainer
Hunter, Ewan
Ibberson, Mark
Ioannidis, Vassilios
Kugler, Sabine
Lories, Rik J.
Resch, Eduard
Rüping, Stefan
Scholich, Klaus
Schwenk, Jochen M.
Waddington, James C.
Whitfield, Phil
Geisslinger, Gerd
FitzGerald, Oliver
Behrens, Frank
Pennington, Stephen R.
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title_full Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title_fullStr Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title_full_unstemmed Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title_short Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
title_sort omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598654/
https://www.ncbi.nlm.nih.gov/pubmed/36289648
http://dx.doi.org/10.3390/biomedicines10102387
work_keys_str_mv AT gurkerobert omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT bendesannika omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT bowesjohn omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT koehmmichaela omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT twymanrichardm omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT bartonanne omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT elewautdirk omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT goodyearcarl omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT hahnefeldlisa omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT hillenbrandrainer omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT hunterewan omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT ibbersonmark omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT ioannidisvassilios omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT kuglersabine omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT loriesrikj omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT rescheduard omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT rupingstefan omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT scholichklaus omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT schwenkjochenm omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT waddingtonjamesc omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT whitfieldphil omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT geisslingergerd omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT fitzgeraldoliver omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT behrensfrank omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT penningtonstephenr omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis
AT omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis